SCHEMBL2471752

SCHEMBL2471752

COCc1cc([N+](=O)[O-])ccc1-n1cccc(Br)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
F2RL3 Q96RI0 2/20 0.39
CHEK1 O14757 1/20 0.38
PIM1 P11309 1/20 0.38
LIMK1 P53667 1/20 0.38
TYRO3 Q06418 1/20 0.38
MAPK14 Q16539 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
LMNA P02545 3/20 0.35
HPGD P15428 1/20 0.35
CYP1A2 P05177 1/20 0.35
CASP1 P29466 1/20 0.35
CASP3 P42574 1/20 0.35
CASP4 P49662 1/20 0.35
CASP7 P55210 1/20 0.35
CASP9 P55211 1/20 0.35
CASP6 P55212 1/20 0.35
ALDH1A1 P00352 3/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750648 0.87 F2RL3 (0.40) MEN1KMT2AF2RL3LMNAHPGD
SCHEMBL3644933 0.86 MAPT (0.44) MEN1KMT2AF2RL3LMNAHPGD
SCHEMBL2475555 0.84 F2 (0.44) MEN1KMT2AF2RL3LMNAHPGD
SCHEMBL2474307 0.83 F2RL3 (0.38) MEN1KMT2AF2RL3LMNAHPGD
SCHEMBL12179475 0.82 CYP1A2 (0.43) MEN1KMT2AF2RL3LMNACYP1A2
SCHEMBL2477846 0.82 HTT (0.47) MEN1KMT2ACHEK1PIM1LIMK1
SCHEMBL14924764 0.82 F2 (0.34) MEN1KMT2ALMNAHPGDCYP1A2
SCHEMBL2473608 0.80 ALDH1A1 (0.46) MEN1KMT2ACHEK1PIM1LIMK1
SCHEMBL12196584 0.80 ALDH1A1 (0.35) MEN1KMT2AF2RL3LMNAHPGD
SCHEMBL12179656 0.78 ALDH1A1 (0.37) MEN1KMT2ALMNACYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563762-B1 METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE BAYER IP GMBH (DE) 2015-07-22 EP disclosed
CN-102906071-B Method for producing substituted pyridin-2-one BAYER IP GMBH 2015-03-18 CN disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8802860-B2 Method for producing substituted pyridin-2-one BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-12 US disclosed
US-8802860-B2 Method for producing substituted pyridin-2-one BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-12 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
EP-2173744-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION Bayer Pharma AG (DE) 2011-10-05 EP disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
EP-2173744-A1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION Bayer HealthCare AG (DE) 2010-04-14 EP disclosed
WO-2008155033-A1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed
WO-2008155032-A1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L MEN1 1705/4885KMT2A 3284/4885F2RL3 1571/4885
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L MEN1 1705/4885KMT2A 3284/4885F2RL3 1571/4885
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L MEN1 1705/4885KMT2A 3284/4885F2RL3 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.